The Infusion Blog
Blog articles are primarily written by voices of the infusion industry. The opinions of guest authors do not necessarily represent or reflect the opinions or positions of NICA.
By: Tiffani Bouchard, CCS Managing JW and JZ Modifiers When Billing Single-Dose Drugs Managing JW and JZ modifiers when billing single-dose drugs can be challenging. As you may know, the Medicare Program has been requiring the use of the JW modifier (Drug amount discarded and not administered to any patient) for some time now. It is commonly understood this modifier is required to report the drug wastage when a separately payable drug or biological is
By: Pamela McIntyre, CRNI, IgCN, OCN, and VA-BC Maximizing Efficiency in Ambulatory Infusion Centers When it comes to maximizing efficiency in ambulatory infusion centers, one of the most frequently asked questions infusion center managers have is how to determine the appropriate ratio of nurses to patients at their infusion centers. This is a valid concern as we all grapple with maintaining fiscal viability in the era of reimbursement challenges and retention of skilled team members.
By: Michael Rigas, Pharm.D., FNHIA Biosimilars are also known as follow-on biologics or subsequent-entry biologics. They are FDA-approved copies of the original “innovator” drug product that are allowed to be licensed and approved by the FDA once the innovator product’s patent expires. The Biologics Price and Competition Act (BPCA) was introduced by Senator Edward Kennedy in 2007 and was passed by Congress and signed by President Obama in 2010 as part of the Patient Protection
By: Ty Bello, BS, RCC The objective of this article is to provide information with application so you, as an Independent Ambulatory Infusion Center, can either begin the sales journey or accelerate the existing sales process in your business. So regardless of whether or not you have a sales team, this article will provide insight and information that can move the needle on your sales process and team. To approach this topic so broadly, we
By: Kay Coulter, RN, CRNI, VA-BC In the insurance industry there’s a saying about how you don’t know you’re facing litigation until it’s too late. Ambulatory Infusion Center providers can tell you risk management is key to protecting patients from harm and staff from lawsuits. IV Therapy Practice Pearls will offer current evidence-based principles, practice points and information related to the placement of peripheral vascular access devices, as well as the delivery of IV fluids
What’s behind the recent surge of investments into the infusion industry? The ambulatory infusion center (AIC) industry has seen a significant surge in investment in recent years. This trend is driven by a number of factors, including an aging population, an increase in chronic diseases, and a shift towards more cost-effective, out-of-hospital care. What Is Private Equity? Private equity is a broad term which generally refers to private investment funds that make investments in privately
The following post was authored in partnership with NICA partner, SamaCare. Prior authorizations are a burden across all specialties. In fact, in a 2022 survey by SamaCare, 91% of providers reported that prior authorizations have a “highly negative” or “somewhat negative” effect on patient care. Infusion centers face their own unique set of challenges when it comes to navigating the complex prior authorization landscape. To begin, infusion centers typically deal with a high volume of